User contributions
Jump to navigation
Jump to search
- 23:11, 22 April 2024 diff hist +6 m Multiple myeloma - historical
- 23:10, 22 April 2024 diff hist +7 m Multiple myeloma - historical →Subsequent treatment
- 23:06, 22 April 2024 diff hist +1,516 N Nogapendekin alfa inbakicept (Anktiva) Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nogapendekin-alfa NCI Drug Dictionary]: A fusion protein complex composed of..." current
- 23:00, 22 April 2024 diff hist +74 m Drug index →N
- 13:14, 22 April 2024 diff hist +14 m Breast cancer, ER-positive →Adjuvant therapy, premenopausal
- 13:13, 22 April 2024 diff hist +2,251 m Breast cancer, ER-positive →Goserelin & Tamoxifen {{#subobject:23ef1e|Regimen=1}}
- 13:13, 22 April 2024 diff hist +12 m Breast cancer, ER-positive
- 13:12, 22 April 2024 diff hist +2,256 Breast cancer, ER-positive →Adjuvant therapy, premenopausal
- 13:09, 22 April 2024 diff hist +2,763 m Breast cancer, ER-positive →Anastrozole monotherapy {{#subobject:a052f4|Regimen=1}}
- 13:05, 22 April 2024 diff hist +2 m Breast cancer, ER-positive
- 13:05, 22 April 2024 diff hist +2,760 Breast cancer, ER-positive →Letrozole monotherapy {{#subobject:55e6f9|Regimen=1}}
- 12:52, 22 April 2024 diff hist +630 m Chronic myeloid leukemia →Imatinib monotherapy {{#subobject:917a16|Regimen=1}}
- 16:46, 21 April 2024 diff hist +6 m Ewing sarcoma
- 16:42, 21 April 2024 diff hist +7 m Esophageal cancer →Subsequent treatment
- 16:40, 21 April 2024 diff hist +7 m Diffuse large B-cell lymphoma →Subsequent treatment
- 16:38, 21 April 2024 diff hist +96 m Classical Hodgkin lymphoma
- 16:34, 21 April 2024 diff hist +7 m Breast cancer →Subsequent treatment
- 16:33, 21 April 2024 diff hist +7 m Breast cancer →Subsequent treatment
- 12:52, 21 April 2024 diff hist +7 m Breast cancer, ER-positive →Preceding treatment
- 12:48, 21 April 2024 diff hist +12 m Breast cancer - historical
- 12:46, 21 April 2024 diff hist -51 m Acute promyelocytic leukemia
- 12:42, 21 April 2024 diff hist +12 m Acute myeloid leukemia - historical →DAT {{#subobject:fc4f58|Regimen=1}}
- 20:15, 20 April 2024 diff hist +2,200 m Non-small cell lung cancer →Carboplatin & Docetaxel {{#subobject:bdce59|Regimen=1}}
- 20:06, 20 April 2024 diff hist +1,560 m Breast cancer - historical →STAMP-I {{#subobject:c08ab4|Regimen=1}}
- 20:05, 20 April 2024 diff hist -1,561 m Breast cancer - historical →VAP {{#subobject:4b99b8|Regimen=1}}
- 20:04, 20 April 2024 diff hist +513 m Breast cancer - historical →CTCb, then auto HSCT {{#subobject:02f569|Regimen=1}}
- 19:55, 20 April 2024 diff hist +2,042 m Breast cancer - historical →CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}
- 19:55, 20 April 2024 diff hist -2,042 m Breast cancer - historical →CTCb, then auto HSCT {{#subobject:02f569|Regimen=1}}
- 19:54, 20 April 2024 diff hist +2,013 m Breast cancer - historical →CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}
- 19:53, 20 April 2024 diff hist +1,366 m Breast cancer - historical →Mitoxantrone & Vinorelbine (MV) {{#subobject:eb48ba|Regimen=1}}
- 19:50, 20 April 2024 diff hist -2,555 m Breast cancer - historical →STAMP-I {{#subobject:c08ab4|Regimen=1}}
- 19:47, 20 April 2024 diff hist +61 m Breast cancer - historical →Metastatic disease, first-line therapy
- 18:32, 20 April 2024 diff hist +118 m Acute myeloid leukemia →Upfront induction therapy, standard and older "fit" patients
- 12:56, 20 April 2024 diff hist +44 m Esophageal cancer →References
- 12:54, 20 April 2024 diff hist +68 m Esophageal cancer
- 00:40, 20 April 2024 diff hist -140 m Cutaneous squamous cell carcinoma
- 00:39, 20 April 2024 diff hist +69 m Classical Hodgkin lymphoma
- 00:37, 20 April 2024 diff hist +845 m Classical Hodgkin lymphoma
- 00:37, 20 April 2024 diff hist -7 m Autologous HSCT →References
- 00:36, 20 April 2024 diff hist +63 m Autologous HSCT →Regimen {{#subobject:81ff2e|Variant=1}}
- 00:22, 20 April 2024 diff hist +35 m Head and neck cancer
- 00:20, 20 April 2024 diff hist +186 m Colorectal cancer
- 00:17, 20 April 2024 diff hist +251 m Non-small cell lung cancer
- 00:11, 20 April 2024 diff hist +69 m Malignant solid neoplasm, ERBB2-mutated →Trastuzumab emtansine monotherapy {{#subobject:0a0a41|Regimen=1}} current
- 00:10, 20 April 2024 diff hist +67 m Malignant solid neoplasm, ERBB2-mutated →Neratinib monotherapy {{#subobject:3c1a9c|Regimen=1}}
- 00:09, 20 April 2024 diff hist +1,507 Malignant solid neoplasm, ERBB2-mutated →Trastuzumab emtansine monotherapy {{#subobject:0a0a41|Regimen=1}}
- 00:03, 20 April 2024 diff hist +453 m Trastuzumab deruxtecan (Enhertu) current
- 23:55, 19 April 2024 diff hist 0 m Urothelial carcinoma
- 23:50, 19 April 2024 diff hist +3 m Melanoma →Regimen variant #1, 2 mg/kg q3wk {{#subobject:25a9fe|Variant=1}}
- 23:49, 19 April 2024 diff hist +3 m Melanoma →Regimen variant #2, indefinite {{#subobject:722e51|Variant=1}}
- 16:37, 19 April 2024 diff hist +230 m Opioid Conversion Table current
- 16:22, 19 April 2024 diff hist +745 m B-cell acute lymphoblastic leukemia, pediatric →References
- 12:34, 19 April 2024 diff hist 0 m Mantle cell lymphoma →Lenalidomide monotherapy {{#subobject:b5de78|Regimen=1}}
- 12:32, 19 April 2024 diff hist +594 m Head and neck cancer →Methotrexate monotherapy {{#subobject:0e90b2|Regimen=1}}
- 12:30, 19 April 2024 diff hist +280 m Glioblastoma →Carmustine & RT {{#subobject:ee9fbd|Regimen=1}}
- 12:25, 19 April 2024 diff hist +293 m Head and neck cancer →Cetuximab monotherapy {{#subobject:4b973b|Regimen=1}}
- 12:24, 19 April 2024 diff hist +933 m Head and neck cancer →Docetaxel monotherapy {{#subobject:623c3f|Regimen=1}}
- 12:15, 19 April 2024 diff hist -36 m B-cell acute lymphoblastic leukemia, Ph-positive →Dasatinib, Vincristine, Prednisone {{#subobject:71a41c|Regimen=1}}
- 12:11, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →Regimen {{#subobject:bd7f87|Variant=1}}
- 12:11, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →FLAG-Ida {{#subobject:d8c75b|Regimen=1}}
- 12:10, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →Regimen {{#subobject:c9nqa0|Variant=1}}
- 11:17, 19 April 2024 diff hist +337 m Chronic lymphocytic leukemia →Ofatumumab monotherapy {{#subobject:75bd7e|Regimen=1}}
- 11:12, 19 April 2024 diff hist -4 m Breast cancer, triple negative
- 11:11, 19 April 2024 diff hist -1 m Breast cancer, triple negative →Paclitaxel & Pembrolizumab {{#subobject:2g8gua|Regimen=1}}
- 11:07, 19 April 2024 diff hist +29 m Breast cancer, BRCA-mutated →Regimen variant #2, 300 mg twice per day {{#subobject:3b0774|Variant=1}}
- 11:00, 19 April 2024 diff hist +8 m Colorectal cancer, MSI-H or dMMR →Regimen {{#subobject:3af038|Variant=1}}
- 11:00, 19 April 2024 diff hist +2 m Colorectal cancer, MSI-H or dMMR →Regimen {{#subobject:3af038|Variant=1}}
- 10:59, 19 April 2024 diff hist -65 m Colorectal cancer, MSI-H or dMMR →Pembrolizumab monotherapy {{#subobject:5aa59d|Regimen=1}}
- 00:36, 19 April 2024 diff hist -1 m Esophageal squamous cell carcinoma →Nivolumab monotherapy {{#subobject:10ee99|Regimen=1}}
- 00:35, 19 April 2024 diff hist -1 m Esophageal squamous cell carcinoma →Regimen {{#subobject:d1dde0|Variant=1}}
- 00:35, 19 April 2024 diff hist +29 m Esophageal squamous cell carcinoma →Camrelizumab monotherapy {{#subobject:c701c3|Regimen=1}}
- 00:29, 19 April 2024 diff hist -39 m Non-small cell lung cancer, nonsquamous →Regimen variant #2, 5/500 x 4, then maintenance pem x 2y {{#subobject:1mwjm3|Variant=1}}
- 00:19, 19 April 2024 diff hist +1,816 Ovarian cancer, HRD-positive →Paclitaxel monotherapy {{#subobject:f47paa|Regimen=1}}
- 00:17, 19 April 2024 diff hist +1,791 Ovarian cancer, HRD-positive →Paclitaxel monotherapy {{#subobject:f47paa|Regimen=1}}
- 00:16, 19 April 2024 diff hist +1,794 Ovarian cancer, HRD-positive →Olaparib monotherapy {{#subobject:f47yha|Regimen=1}}
- 00:14, 19 April 2024 diff hist +686 m Ovarian cancer, HRD-positive
- 00:14, 19 April 2024 diff hist -686 m Ovarian cancer, HRD-positive
- 00:13, 19 April 2024 diff hist +1,813 Ovarian cancer, HRD-positive →Olaparib monotherapy {{#subobject:f47yha|Regimen=1}}
- 23:47, 18 April 2024 diff hist -2 m Gastric cancer, HER2-positive →Regimen {{#subobject:577cd6|Variant=1}}
- 23:44, 18 April 2024 diff hist +3 m Peripheral T-cell lymphoma →References
- 23:44, 18 April 2024 diff hist +19 m Peripheral T-cell lymphoma →Gemcitabine monotherapy {{#subobject:7dbc1c|Regimen=1}}
- 23:43, 18 April 2024 diff hist +2 m Peripheral T-cell lymphoma - historical →References
- 23:39, 18 April 2024 diff hist +807 m Clear cell renal cell carcinoma
- 23:36, 18 April 2024 diff hist +730 m Clear cell renal cell carcinoma - null regimens →Placebo current
- 20:40, 18 April 2024 diff hist +4 m Non-small cell lung cancer, ALK-positive →Regimen {{#subobject:9cef11|Variant=1}}
- 20:39, 18 April 2024 diff hist +255 m Alectinib (Alecensa) →History of changes in FDA indication current
- 17:14, 16 April 2024 diff hist -1 m Drug shortages →Links current
- 19:37, 15 April 2024 diff hist +38 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & TBI, then auto HSCT {{#subobject:9ac748|Regimen=1}}
- 19:31, 15 April 2024 diff hist 0 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & Busulfan, then auto HSCT {{#subobject:71ae0c|Regimen=1}}
- 19:30, 15 April 2024 diff hist +308 m Multiple myeloma - historical →MEL200, then auto HSCT, then MEL220 & Dexamethasone, then auto HSCT {{#subobject:9f3119|Regimen=1}}
- 19:25, 15 April 2024 diff hist +330 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & Busulfan, then auto HSCT {{#subobject:71ae0c|Regimen=1}}
- 19:20, 15 April 2024 diff hist -1 m Multiple myeloma, consolidation and maintenance →Thalidomide & Prednisolone (TP) {{#subobject:1agdc9|Regimen=1}}
- 18:42, 15 April 2024 diff hist +255 m Follicular lymphoma - historical →131Iodine-Tositumomab monotherapy {{#subobject:f69726|Regimen=1}}
- 17:48, 15 April 2024 diff hist -1 m Breast cancer - historical →CEF/CMF {{#subobject:682333|Regimen=1}}
- 17:04, 15 April 2024 diff hist +16 m CNS lymphoma →Nordic Regimen, younger patients {{#subobject:e571ce|Regimen=1}}
- 17:02, 15 April 2024 diff hist +2 m Rhabdomyosarcoma, pediatric
- 17:35, 14 April 2024 diff hist -39 m Urothelial carcinoma - null regimens →Preceding treatment current
- 17:35, 14 April 2024 diff hist -13 m Urothelial carcinoma →Preceding treatment
- 17:34, 14 April 2024 diff hist +12 m Urothelial carcinoma - null regimens →Preceding treatment
- 17:33, 14 April 2024 diff hist +9 m Testicular cancer →Regimen variant #5, 45/500/100 (modified BEP) {{#subobject:fd61db|Variant=1}}
- 17:31, 14 April 2024 diff hist +328 m Osteosarcoma - null regimens current
- 17:29, 14 April 2024 diff hist +45 m Non-small cell lung cancer, nonsquamous →Maintenance after first-line therapy
- 17:28, 14 April 2024 diff hist +33 m Non-small cell lung cancer, nonsquamous →Consolidation after definitive therapy for inoperable disease
- 17:27, 14 April 2024 diff hist -70 m Non-small cell lung cancer - historical
- 17:25, 14 April 2024 diff hist +74 m Multiple myeloma - historical
- 17:23, 14 April 2024 diff hist +140 m Multiple myeloma, consolidation and maintenance
- 17:21, 14 April 2024 diff hist +9 m Mantle cell lymphoma →Preceding treatment
- 17:20, 14 April 2024 diff hist +26 m Mantle cell lymphoma →Brexucabtagene autoleucel monotherapy {{#subobject:4z3u14|Regimen=1}}
- 17:19, 14 April 2024 diff hist +10 m Low-grade glioma →Regimen variant #3, continuous therapy {{#subobject:3871fe|Variant=1}}
- 17:19, 14 April 2024 diff hist +24 m Light-chain (AL) amyloidosis →Relapsed or refractory
- 17:16, 14 April 2024 diff hist +43 m Glioblastoma →Maintenance after first-line therapy
- 12:49, 14 April 2024 diff hist +44 m Ewing sarcoma
- 12:48, 14 April 2024 diff hist -36 m Acute promyelocytic leukemia
- 12:43, 14 April 2024 diff hist +355 m Diffuse large B-cell lymphoma
- 11:27, 14 April 2024 diff hist +69 m Small cell lung cancer - historical
- 11:09, 14 April 2024 diff hist +1,805 m Paroxysmal nocturnal hemoglobinuria →Iptacopan monotherapy {{#subobject:aa617d |Regimen=1}}
- 10:43, 14 April 2024 diff hist +58 m Paroxysmal nocturnal hemoglobinuria →References
- 10:41, 14 April 2024 diff hist +56 m Drug index →I
- 10:40, 14 April 2024 diff hist -25 m Drug index →I
- 10:40, 14 April 2024 diff hist +125 m Iptacopan (Fabhalta) current
- 10:38, 14 April 2024 diff hist +34 N Iptacopan (LNP-023) Jwarner moved page Iptacopan (LNP-023) to Iptacopan (Fabhalta): FDA approval current Tag: New redirect
- 10:38, 14 April 2024 diff hist 0 m Iptacopan (Fabhalta) Jwarner moved page Iptacopan (LNP-023) to Iptacopan (Fabhalta): FDA approval
- 10:38, 14 April 2024 diff hist +248 m Iptacopan (Fabhalta)
- 10:34, 14 April 2024 diff hist -223 m Pheochromocytoma →Sunitinib monotherapy {{#subobject:ec3261|Regimen=1}}
- 10:33, 14 April 2024 diff hist +2,063 Pheochromocytoma →All lines of therapy
- 15:29, 13 April 2024 diff hist +82 m Follicular lymphoma →Maintenance after subsequent lines of therapy
- 15:27, 13 April 2024 diff hist +55 m Follicular lymphoma →Consolidation after subsequent lines of therapy
- 15:25, 13 April 2024 diff hist +227 m Follicular lymphoma →Maintenance after first-line therapy
- 15:22, 13 April 2024 diff hist +204 m Follicular lymphoma →Consolidation after first-line therapy
- 15:17, 13 April 2024 diff hist +11 m Follicular lymphoma →Observation
- 15:17, 13 April 2024 diff hist +27 m Follicular lymphoma →Radiation therapy {{#subobject:6298df|Regimen=1}}
- 15:14, 13 April 2024 diff hist +10 m Esophageal cancer →Definitive therapy
- 15:13, 13 April 2024 diff hist +11 m Esophageal cancer →Preceding treatment
- 15:12, 13 April 2024 diff hist +1 m Diffuse large B-cell lymphoma →Lenalidomide monotherapy {{#subobject:e4284f|Regimen=1}}
- 15:11, 13 April 2024 diff hist +230 m Diffuse large B-cell lymphoma →Relapsed or refractory, salvage therapy
- 15:06, 13 April 2024 diff hist +61 m Diffuse large B-cell lymphoma
- 15:04, 13 April 2024 diff hist +65 m Diffuse large B-cell lymphoma →Maintenance after upfront therapy
- 15:03, 13 April 2024 diff hist +217 m Diffuse large B-cell lymphoma →Consolidation after upfront therapy
- 15:00, 13 April 2024 diff hist +58 m Diffuse large B-cell lymphoma - null regimens current
- 14:58, 13 April 2024 diff hist +10 m Diffuse large B-cell lymphoma - historical →Consolidation after upfront therapy
- 14:57, 13 April 2024 diff hist +12 m Colorectal cancer →Advanced or metastatic disease, third-line therapy
- 14:56, 13 April 2024 diff hist +33 m Colorectal cancer →Advanced or metastatic disease, second-line therapy
- 14:56, 13 April 2024 diff hist +25 m Colorectal cancer →Advanced or metastatic disease, first-line
- 14:54, 13 April 2024 diff hist +88 m Colorectal cancer →Maintenance after first-line therapy
- 12:54, 13 April 2024 diff hist +77 m CNS lymphoma →Relapsed or refractory, salvage therapy
- 12:54, 13 April 2024 diff hist +285 m CNS lymphoma →Consolidation after upfront therapy
- 12:51, 13 April 2024 diff hist +87 m CNS lymphoma →Upfront therapy, non-randomized or retrospective data
- 12:49, 13 April 2024 diff hist +107 m CNS lymphoma →Upfront therapy, randomized data
- 12:47, 13 April 2024 diff hist +11 m CNS lymphoma →Methotrexate monotherapy {{#subobject:e89965|Regimen=1}}
- 12:47, 13 April 2024 diff hist +20 m CNS lymphoma
- 12:46, 13 April 2024 diff hist +20 m CNS lymphoma - null regimens current
- 11:38, 13 April 2024 diff hist +30 m Pancreatic cancer →Regimen variant #2, q4wk indefinite {{#subobject:fcd708|Variant=1}}
- 11:37, 13 April 2024 diff hist +60 m Pancreatic cancer →Regimen {{#subobject:242770|Variant=1}}
- 11:35, 13 April 2024 diff hist +2,181 Pancreatic cancer →Capecitabine monotherapy {{#subobject:38b5c7|Regimen=1}}
- 00:22, 13 April 2024 diff hist +39 m Classical Hodgkin lymphoma - historical
- 00:20, 13 April 2024 diff hist +79 m Classical Hodgkin lymphoma - null regimens current
- 00:19, 13 April 2024 diff hist +1,517 m Classical Hodgkin lymphoma
- 23:54, 12 April 2024 diff hist +68 m Chronic myeloid leukemia
- 23:53, 12 April 2024 diff hist +13 m Chronic myeloid leukemia →Subsequent treatment
- 23:52, 12 April 2024 diff hist +44 m Chronic myeloid leukemia →Imatinib monotherapy {{#subobject:6cdc45|Regimen=1}}
- 23:49, 12 April 2024 diff hist +14 m Breast cancer, HER2-positive →Preceding treatment
- 23:47, 12 April 2024 diff hist +241 m Breast cancer, ER-positive
- 23:41, 12 April 2024 diff hist +25 m Bladder cancer →Induction chemoradiotherapy
- 23:40, 12 April 2024 diff hist +27 m B-cell acute lymphoblastic leukemia →Preceding treatment
- 23:38, 12 April 2024 diff hist +10 m Anaplastic glioma →Preceding treatment
- 18:31, 12 April 2024 diff hist +2,514 m Clear cell renal cell carcinoma
- 18:26, 12 April 2024 diff hist +944 m Breast cancer - null regimens →References
- 18:26, 12 April 2024 diff hist +944 m Breast cancer, BRCA-mutated →References
- 18:06, 12 April 2024 diff hist +16 m CARv3-TEAM-E T-cells current
- 18:05, 12 April 2024 diff hist +658 N CARv3-TEAM-E T-cells Created page with "==Mechanism of action== anti-EGFR CAR T-cells ==Preliminary data== ===Glioblastoma=== #'''INCIPIENT:''' Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Ni..."
- 18:03, 12 April 2024 diff hist +26 m Drug index →C
- 18:00, 12 April 2024 diff hist +34 N Category:SPEAR T-cells Created page with "Category:Immune effector cells" current
- 18:00, 12 April 2024 diff hist +26 N Category:Anti-MAGE-A4 SPEAR T-cells Created page with "Category:SPEAR T-cells" current
- 17:59, 12 April 2024 diff hist -35 m Afamitresgene Autoleucel (ADP-A2M4) current
- 17:59, 12 April 2024 diff hist +36 N Category:Liposarcoma medications (investigational) Created page with "Category:Liposarcoma medications" current
- 17:59, 12 April 2024 diff hist +1,888 N Afamitresgene Autoleucel (ADP-A2M4) Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afamitresgene-autoleucel NCI Drug Dictionary]: A preparation of autologous h..."
- 17:54, 12 April 2024 diff hist +41 m Drug index →A
- 10:17, 12 April 2024 diff hist +81 m Breast cancer, ER-positive - null regimens current
- 10:15, 12 April 2024 diff hist +8,424 m Breast cancer - historical →CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}
- 10:15, 12 April 2024 diff hist -8,424 m Breast cancer - historical →CAV {{#subobject:90f8d0|Regimen=1}}
- 00:18, 12 April 2024 diff hist +3,422 Non-small cell lung cancer, ALK-positive →Carboplatin & Pemetrexed {{#subobject:b94ckc|Regimen=1}}
- 00:16, 12 April 2024 diff hist +3,428 Non-small cell lung cancer, ALK-positive →Cisplatin & Pemetrexed {{#subobject:b9uc2c|Regimen=1}}
- 00:13, 12 April 2024 diff hist 0 m Non-small cell lung cancer, ALK-positive →Regimen variant #2, 750 mg/day fasting {{#subobject:47c6e4|Variant=1}}
- 00:13, 12 April 2024 diff hist +4 m Non-small cell lung cancer, ALK-positive
- 00:12, 12 April 2024 diff hist +1,691 m Non-small cell lung cancer, ALK-positive →Carboplatin & Pemetrexed {{#subobject:b94ckc|Regimen=1}}
- 17:47, 11 April 2024 diff hist +6 m Non-small cell lung cancer, ALK-positive
- 17:47, 11 April 2024 diff hist +1,691 Non-small cell lung cancer, ALK-positive →Alectinib monotherapy {{#subobject:bbc3cc|Regimen=1}}
- 15:48, 11 April 2024 diff hist +6 m Non-small cell lung cancer, ALK-positive
- 15:48, 11 April 2024 diff hist +2,021 Non-small cell lung cancer, ALK-positive →Advanced or metastatic disease, ALK inhibitor-naive
- 10:47, 11 April 2024 diff hist +1,029 m Gastric cancer →SOX {{#subobject:ecig8a|Regimen=1}}
- 10:45, 11 April 2024 diff hist +977 m Gastric cancer →SOX {{#subobject:ecig8a|Regimen=1}}
- 12:40, 10 April 2024 diff hist -4,351 m Hereditary hemorrhagic telangiectasia
- 12:40, 10 April 2024 diff hist +5,450 N Hereditary hemorrhagic telangiectasia - null regimens Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;..."
- 12:38, 10 April 2024 diff hist +265 m Hereditary hemorrhagic telangiectasia
- 12:27, 10 April 2024 diff hist +30 m Sickle cell anemia
- 12:27, 10 April 2024 diff hist +1,575 m Sickle cell anemia - null regimens →Placebo {{#subobject:9149f2|Regimen=1}} current
- 12:25, 10 April 2024 diff hist +7,736 N Sickle cell anemia - null regimens Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;..."
- 12:25, 10 April 2024 diff hist -2,018 m Sickle cell anemia
- 12:21, 10 April 2024 diff hist +246 m Sickle cell anemia
- 11:22, 10 April 2024 diff hist +215 m Smoldering multiple myeloma
- 11:21, 10 April 2024 diff hist -4,761 m Smoldering multiple myeloma
- 11:21, 10 April 2024 diff hist +5,684 N Smoldering multiple myeloma - null regimens Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;..." current
- 11:19, 10 April 2024 diff hist +255 m Smoldering multiple myeloma
- 11:48, 9 April 2024 diff hist +13 m Vincristine liposomal (Marqibo) →History of changes in FDA indication current
- 11:47, 9 April 2024 diff hist +11 m Tositumomab and I-131 (Bexxar) →History of changes in FDA indication - PARTIALLY WITHDRAWN current
- 11:46, 9 April 2024 diff hist +11 m Rucaparib (Rubraca) →History of changes in FDA indication current
- 11:45, 9 April 2024 diff hist +251 m Pembrolizumab (Keytruda) →Small cell lung cancer - WITHDRAWN current
- 11:45, 9 April 2024 diff hist +424 m Pembrolizumab (Keytruda) →Gastric or gastroesophageal junction adenocarcinoma - PARTIALLY WITHDRAWN
- 11:44, 9 April 2024 diff hist +12 m Panobinostat (Farydak) →History of changes in FDA indication current
- 11:43, 9 April 2024 diff hist +14 m Olaratumab (Lartruvo) →History of changes in FDA indication current
- 11:41, 9 April 2024 diff hist +107 m Umbralisib (Ukoniq) →History of changes in FDA indication current
- 11:38, 9 April 2024 diff hist +8 m Ibrutinib (Imbruvica) →History of changes in FDA indication - PARTIALLY WITHDRAWN current
- 11:38, 9 April 2024 diff hist +385 m Ibrutinib (Imbruvica) →History of changes in FDA indication
- 11:36, 9 April 2024 diff hist +308 m Pralsetinib (Gavreto) →History of changes in FDA indication current
- 11:34, 9 April 2024 diff hist +31 N Category:FDA withdrawn in 2024 Created page with "Category:Discontinued drugs" current
- 11:33, 9 April 2024 diff hist +225 m Copanlisib (Aliqopa) current
- 11:30, 9 April 2024 diff hist +10 m Olaparib (Lynparza) →Ovarian cancer - PARTIALLY WITHDRAWN current
- 11:30, 9 April 2024 diff hist +12 m Nivolumab (Opdivo) →Small cell lung cancer - WITHDRAWN current
- 11:29, 9 April 2024 diff hist +12 m Nivolumab (Opdivo) →Hepatocellular carcinoma - PARTIALLY WITHDRAWN
- 11:29, 9 April 2024 diff hist +13 m Melphalan flufenamide (Pepaxto) →Multiple myeloma - WITHDRAWN current
- 11:23, 9 April 2024 diff hist +21 m Idelalisib (Zydelig) →History of changes in FDA indication current
- 11:23, 9 April 2024 diff hist +12 m Gemtuzumab ozogamicin (Mylotarg) →History of changes in FDA indication current
- 11:22, 9 April 2024 diff hist +12 m Gefitinib (Iressa) →Non-small cell lung cancer - PARTIALLY WITHDRAWN current
- 11:21, 9 April 2024 diff hist -116 m Duvelisib (Copiktra) →History of changes in FDA indication current
- 11:18, 9 April 2024 diff hist +12 m Bevacizumab (Avastin) →Breast cancer - WITHDRAWN current
- 11:17, 9 April 2024 diff hist +24 m Atezolizumab (Tecentriq) →Urothelial carcinoma - WITHDRAWN current
- 11:17, 9 April 2024 diff hist +12 m Atezolizumab (Tecentriq) →Breast cancer, triple negative - WITHDRAWN
- 00:50, 9 April 2024 diff hist +27 m Soft tissue sarcoma
- 00:50, 9 April 2024 diff hist 0 m Soft tissue sarcoma - null regimens current
- 00:49, 9 April 2024 diff hist +23 m Testicular cancer →Consolidation after salvage therapy
- 00:43, 9 April 2024 diff hist +81 m Non-small cell lung cancer →Maintenance after first-line therapy
- 00:42, 9 April 2024 diff hist +277 m Non-small cell lung cancer
- 23:59, 8 April 2024 diff hist +150 m Non-small cell lung cancer - null regimens current
- 22:15, 8 April 2024 diff hist +128 m Anaplastic glioma
- 20:55, 8 April 2024 diff hist +58 m Acute myeloid leukemia →Relapsed or refractory, salvage therapy
- 20:54, 8 April 2024 diff hist +21 m Acute myeloid leukemia →Maintenance after first-line therapy
- 20:53, 8 April 2024 diff hist +405 m Acute myeloid leukemia →Consolidation after upfront therapy
- 20:49, 8 April 2024 diff hist +99 m Acute myeloid leukemia →First-line induction therapy, older or "unfit" patients
- 20:47, 8 April 2024 diff hist +48 m Acute myeloid leukemia →Subsequent induction therapy, standard and older "fit" patients
- 20:47, 8 April 2024 diff hist +375 m Acute myeloid leukemia →Upfront induction therapy, standard and older "fit" patients
- 20:40, 8 April 2024 diff hist +30 m Multiple myeloma - null regimens current
- 20:39, 8 April 2024 diff hist +79 m Follicular lymphoma - historical
- 20:36, 8 April 2024 diff hist +128 m Esophageal cancer
- 20:32, 8 April 2024 diff hist +36 m Acute myeloid leukemia, pediatric - historical
- 20:31, 8 April 2024 diff hist +44 m Acute myeloid leukemia, pediatric →Consolidation after salvage therapy current
- 20:30, 8 April 2024 diff hist +14 m Acute myeloid leukemia, pediatric →Relapsed or refractory, salvage therapy
- 20:30, 8 April 2024 diff hist +38 m Acute myeloid leukemia, pediatric →Consolidation after upfront therapy
- 20:29, 8 April 2024 diff hist +43 m Acute myeloid leukemia, pediatric →Upfront induction therapy
- 20:29, 8 April 2024 diff hist +10 m Acute myeloid leukemia, pediatric
- 20:25, 8 April 2024 diff hist +14 m Acute promyelocytic leukemia →Consolidation after salvage therapy